Literature DB >> 18269664

Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus.

Giovanni Corrocher1, Gabriele Di Lorenzo, Nicola Martinelli, Pasquale Mansueto, Domenico Biasi, Pier Francesco Nocini, Giorgio Lombardo, Andrea Fior, Roberto Corrocher, Lisa Maria Bambara, Stefano Gelio, Maria Luisa Pacor.   

Abstract

BACKGROUND: Oral lichen planus (OLP) is considered to be an autoimmune disease of unknown aetiology that affects the mucosae, especially the oral cavity.
OBJECTIVE: We compared tacrolimus 0.1% ointment and clobetasol 0.05% ointment for the treatment of OLP. PATIENTS AND METHODS: A total of 32 patients (20 females and 12 males; all white, Italian origin, mean age of 43.6+/-18.4 years; 16 patients per treatment group) were treated with tacrolimus or clobetasol ointment for 4 weeks in a randomized, double-blind, clinical trial. Pain severity, burning sensation, and mucosal lesion extension were assessed using a four-point scale.
RESULTS: At the end of the treatment period, symptom scores were significantly lower in the tacrolimus group than in the clobetasol group.
CONCLUSION: The results of this study suggest that tacrolimus 0.1% ointment is more effective than clobetasol propionate 0.05% ointment in the treatment of OLP. However, other studies are needed to confirm the effectiveness of this treatment before it can be recommended for use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18269664     DOI: 10.1111/j.1600-051X.2007.01191.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  9 in total

1.  Treatment of geographic tongue with topical tacrolimus.

Authors:  Jigar M Purani; Hiral J Purani
Journal:  BMJ Case Rep       Date:  2014-08-01

Review 2.  Medical Management of Oral Lichen Planus: A Systematic Review.

Authors:  Swetha Singh Suresh; Krunal Chokshi; Sachin Desai; Rahul Malu; Achala Chokshi
Journal:  J Clin Diagn Res       Date:  2016-02-01

3.  [Ulcerated plantar lichen planus. Successful treatment with cyclosporine].

Authors:  R Renner; R Treudler; C Gebhardt; J C Simon
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

Review 4.  Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis.

Authors:  Eduardo Liberato da Silva; Taiane Berguemaier de Lima; Pantelis Varvaki Rados; Fernanda Visioli
Journal:  Clin Oral Investig       Date:  2021-08-03       Impact factor: 3.573

5.  Cutaneous manifestations of viral hepatitis.

Authors:  Ahmed Akhter; Adnan Said
Journal:  Curr Infect Dis Rep       Date:  2015-02       Impact factor: 3.663

6.  Interventions for treating oral lichen planus: corticosteroid therapies.

Authors:  Giovanni Lodi; Maddalena Manfredi; Valeria Mercadante; Ruth Murphy; Marco Carrozzo
Journal:  Cochrane Database Syst Rev       Date:  2020-02-28

7.  Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.

Authors:  Sophie Dupuis-Girod; Anne-Emmanuelle Fargeton; Vincent Grobost; Sophie Rivière; Marjolaine Beaudoin; Evelyne Decullier; Lorraine Bernard; Valentine Bréant; Bettina Colombet; Pierre Philouze; Sabine Bailly; Frédéric Faure; Ruben Hermann
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

8.  Comparison of topical clobetasol propionate 0.05% and topical tacrolimus 0.1% in the treatment of cutaneous lichen planus.

Authors:  Ezgi Özkur; Esra Koku Aksu; Mehmet Salih Gürel; Sevil Savaş
Journal:  Postepy Dermatol Alergol       Date:  2020-01-14       Impact factor: 1.837

9.  Oral lichen planus: comparative efficacy and treatment costs-a systematic review.

Authors:  Shaiba Sandhu; Brittany A Klein; Malak Al-Hadlaq; Prazwala Chirravur; Amal Bajonaid; Yuanming Xu; Rossella Intini; Mai Hussein; Piamkamon Vacharotayangul; Herve Sroussi; Nathaniel Treister; Stephen Sonis
Journal:  BMC Oral Health       Date:  2022-05-06       Impact factor: 3.747

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.